D. E. Shaw & Co., Inc. Immunity Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 520,053 shares of IBRX stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

520,053

Holding current value

$1.39 Million

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.32 - $6.7 $1.73 Million - $3.48 Million	520,053 New	520,053 $1.93 Million
Q1 2024 May 15, 2024	SELL	$3.23 - $6.17 $1.14 Million - $2.19 Million	-354,467 Reduced 59.97%	236,634 $1.27 Million
Q4 2023 Feb 14, 2024	BUY	$1.25 - $5.21 $738,876 - $3.08 Million	591,101 New	591,101 $2.97 Million
Q3 2022 Nov 14, 2022	BUY	$3.65 - $6.43 $977,568 - $1.72 Million	267,827 Added 65.22%	678,504 $3.37 Million
Q2 2022 Aug 15, 2022	BUY	$2.68 - $6.14 $845,296 - $1.94 Million	315,409 Added 331.08%	410,677 $1.53 Million
Q1 2022 May 16, 2022	SELL	$5.05 - $7.53 $1.19 Million - $1.77 Million	-235,233 Reduced 71.17%	95,268 $534,000
Q4 2021 Feb 14, 2022	SELL	$5.67 - $10.18 $266,314 - $478,144	-46,969 Reduced 12.44%	330,501 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$9.17 - $14.24 $2.69 Million - $4.17 Million	293,098 Added 347.39%	377,470 $3.68 Million
Q2 2021 Aug 16, 2021	BUY	$13.41 - $22.4 $1.13 Million - $1.89 Million	84,372 New	84,372 $1.21 Million

Others Institutions Holding IBRX

# of Institutions

204

Shares Held

70M

Call Options Held

1.68M

Put Options Held

1.31M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.07B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account